Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

Core Insights - Highmark Blue Cross Blue Shield has issued a positive coverage policy for Lucid Diagnostics' EsoGuard® Esophageal DNA Test, which will cover non-invasive screening for esophageal precancer and cancer in New York state [1][2] - This decision is seen as a landmark event for Lucid, potentially influencing other commercial insurers to adopt similar coverage policies and validating the strength of Lucid's clinical evidence [2] - Lucid Diagnostics focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, with its EsoGuard® test being the first commercially available tool aimed at early detection [3] Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [3] - The company aims to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk patients, utilizing its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device [3]